KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Long-Term Investments (2019 - 2025)

Historic Long-Term Investments for Royalty Pharma (RPRX) over the last 7 years, with Q3 2025 value amounting to $302.5 million.

  • Royalty Pharma's Long-Term Investments fell 5397.84% to $302.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $302.5 million, marking a year-over-year decrease of 5397.84%. This contributed to the annual value of $693.5 million for FY2024, which is 5865.93% up from last year.
  • According to the latest figures from Q3 2025, Royalty Pharma's Long-Term Investments is $302.5 million, which was down 5397.84% from $275.9 million recorded in Q2 2025.
  • Royalty Pharma's Long-Term Investments' 5-year high stood at $693.5 million during Q4 2024, with a 5-year trough of $275.9 million in Q2 2025.
  • For the 5-year period, Royalty Pharma's Long-Term Investments averaged around $442.6 million, with its median value being $418.2 million (2022).
  • Its Long-Term Investments has fluctuated over the past 5 years, first soared by 7375.51% in 2024, then plummeted by 5619.72% in 2025.
  • Royalty Pharma's Long-Term Investments (Quarter) stood at $435.4 million in 2021, then decreased by 8.78% to $397.2 million in 2022, then grew by 10.05% to $437.1 million in 2023, then skyrocketed by 58.66% to $693.5 million in 2024, then plummeted by 56.38% to $302.5 million in 2025.
  • Its Long-Term Investments stands at $302.5 million for Q3 2025, versus $275.9 million for Q2 2025 and $336.2 million for Q1 2025.